Steven Kelly, Carisma CEO and president
Carisma's CAR-M steals spotlight among 42 bidders to reverse merge with Sesen Bio
Sesen Bio’s decade-plus journey is over after failing to secure a bladder cancer drug approval and carve its own path for IL-6 antibodies. The Cambridge …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.